qipp plans


Supporting QIPP delivery plans – West Leicestershire CCG – May 2016 

This scheme has demonstrated successful outcomes for a collaborative project between Leicester City CCG and Community Pharmacy via the LPC in 2015. this collaborative project  is now being rolled out in West Leicestershire CCG to support CCG QIPP plans and support medicines optimisation/adherence to improve patient outcomes.

West Leicestershire CCG are currently undertaking a switching programme to switch patients from Symbicort to Duoresp (subject to suitability and appropriateness for the patient).

The CCG have asked for Community Pharmacist support for the switch and inform you of the change in advance of the transition which will enable us to manage our supplies and also provide patient support and support medicines optimisation and improve patient outcomes. GP’s have been informed of this and will be switching at practice level and referring patients for an NMS.

How can we support;

1.If you see any generic prescriptions for budesonide/formoterol 200/6 or 400/12 and are supplying Duoresp 160/4.5 or 320/9 – please could you inform the prescriber as we want to ensure that all patients are prescribed inhalers by brand to avoid confusion.

  1. If you see that the patient has been changed from Symbicort or supplied Duoresp for the first time (there should be a script note to alert you to this) – please provide inhaler technique counselling and an NMS (which will help the patient and allow us to be funded for providing this service). An NMS can be performed if there has been a change in formulation such as an inhaler change

This is a West Leicestershire programme and TEVA will also be visiting your pharmacies to provide placebo inhalers and provide support/ training.

The reps are happy to bring placebos and train pharmacists in the correct inhaler technique for using DuoResp Spiromax devices as well as supporting literature which will help pharmacists counsel the patients. The reps are contactable on mobiles or via email:

Yogesh Dave 07867 141220 yogesh.dave@teva.com

Sarw’at Zubair 07980 772 749 sarwat.zubair01@tevauk.com

You will be seeing this transition so I would be grateful if you could ensure that the above is implemented to support formulary implementatation and using our clinical skills to support patient care whilst receiving funding through provision of an NMS service.

If you are not providing NMS – this is a great opportunity to start. These types of interventions will help us to prepare for the future changes and ensure we earn additional income.

I would be grateful if you could print this and share with your Pharmacists, teams and locums to ensure we support this.

The communication from the CCG is below’

The Leicestershire wide formulary has been recently updated to include the DuoResp Spiromax inhaler as an option in both asthma and COPD management. This inhaler contains budesonide and formoterol.

West Leicestershire CCG have recently begun a gradual programme of switching suitable patients currently prescribed Symbicort (or generically written Budesonide/Formoterol) to an equivalent DuoResp Spiromax inhaler.

DuoResp Spiromax 320/9  – equivalent to Symbicort 400/12 (or generically written Budesonide 400/ Formoterol 12)

DuoResp Spiromax 160/4.5 – equivalent to Symbicort 200/6 (or generically written Budesonide 200/ Formoterol 6)

In order to ensure appropriate use of the inhaler our community pharmacist colleagues are encouraged to offer the relevant counselling and inhaler technique coaching when a patient presents with their first prescription. Further to this our local NHS England colleagues have advised that such patients switched onto the DuoResp inhaler, who were previously prescribed Symbicort, are eligible to benefit from the New Medicine Service.

TEVA are offering support for community pharmacists during this switch. The reps are happy to bring placebos and train pharmacists in the correct inhaler technique for using DuoResp Spiromax devices as well as supporting literature which will help pharmacists counsel the patients. The reps are contactable on mobiles or via email:

Yogesh Dave 07867 141220 yogesh.dave@teva.com

Sarw’at Zubair 07980 772 749 sarwat.zubair01@tevauk.com

Please could pharmacists continue to inform prescribers of any generic prescriptions for budesonide/formoterol that need changing to branded Duoresp because the patient is receiving Duoresp Spiromax from the pharmacy.”